Protection against bovine leukemia virus infection by use of inactivated vaccines in cattle.
The protective effects of vaccines made from the viral materials of LK15 cell line (LK15 vaccine) or bat lung cell line (Bat2cl1; Bat vaccine) infected with bovine leukemia virus (BLV) were examined in cattle. Twelve cattle were vaccinated twice at 4-week interval then challenged 4 weeks after the second inoculation. Nine cattle vaccinated with the LK15 vaccine produced antibody to BLV-specific glycoprotein (gp), and the titers ranged from 1:16 to 1:64 by the agar gel immunodiffusion test. Four cattle challenged with 100 microliters (70 to 100 syncytia) of cow blood persistently infected with BLV were protected from infection. However, of the remaining 5 cattle challenged with 500 microliters of infected blood, only 2 were protected. Of the three cattle vaccinated with the Bat vaccine, gp antibody titers ranged from 1:8 to 1:64. Two of them were protected against the challenge with 100 microliters of infected blood. Two cattle protected against the challenge were rechallenged 32 weeks after the first vaccination and not protected. On the other hand, 2 animals protected against the challenge were revaccinated with the LK15 vaccine 32 weeks after the first vaccination. They protected against rechallenge. The results show that all cattle which had gp antibody titers of 1:16 or above were protective against challenge with 100 microliters of the infected blood.
Fukuyama
S
S
Division of Veterinary Microbiology, Kyoto Biken Laboratories, Uji, Japan.
Kodama
K
K
Hirahara
T
T
Nakajima
N
N
Takamura
K
K
Sasaki
O
O
Imanishi
J
J
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D000956:Antigens, Viral / Q000276:immunology; D002417:Cattle; D002460:Cell Line; D002685:Chiroptera; D016583:Enzootic Bovine Leukosis / Q000517:prevention & control*; D007117:Immunization, Secondary; D001909:Leukemia Virus, Bovine / Q000276:immunology* / Q000302:isolation & purification; D008214:Lymphocytes / Q000382:microbiology; D015682:Retroviridae Proteins, Oncogenic / Q000276:immunology; D014407:Tumor Cells, Cultured; D015164:Vaccines, Inactivated; D014765:Viral Vaccines
D000914:Antibodies, Viral; D000956:Antigens, Viral; D015682:Retroviridae Proteins, Oncogenic; D015164:Vaccines, Inactivated; D014765:Viral Vaccines